Company Overview and News

 
Q3 Market Update

2018-10-17 seekingalpha
Who’s concerned about a trade war anyway? That seems to be the U.S. equity market’s take following a robust third quarter despite another $200 billion of Chinese imports targeted for tariffs. Large-cap U.S. equities led the way as investors bored with trade tensions. International and particularly emerging market (EM) equity struggled, likely due to U.S. dollar strength driving contagion concerns in EM.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR WTI COPX QQQC GURU

 
URA / Global X Funds 485BPOS

2018-10-17 sec.gov
Document
URA

 
BOTZ: An Investment In The Automation Revolution

2018-10-16 seekingalpha
Global X Funds BOTZ ETF tracks a thematically cohesive group of stocks focused on the growth of robotics, automation and AI in the global economy.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

 
Uranium, Explained

2018-10-16 seekingalpha
Nuclear power has become an essential source of electricity to meet the world’s growing energy demands, as it can generate power at an enormous scale, is cheaper than many other alternative fuel sources, and emits minimal greenhouse gasses. Countries seek to meet the rapidly growing electricity demand while limiting pollution, and the World Nuclear Association (WNA) expects nuclear generation capacity worldwide to increase to 482GWe by 2035 from 391GWe in 2017, representing 23% growth.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX CCJ SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

 
3 Key Trends In The Robotics Industry

2018-10-16 seekingalpha
We recently attended the RoboBusiness Conference, produced by Robotics Business Review, to hear from leading experts in robotics and automation and to discuss with them the industry’s outlook. We boiled down the conference into three key trends taking place in the robotics industry today:
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

 
Where Preferreds Fit In Your Portfolio

2018-10-16 seekingalpha
Yield potential and relatively high fixed distributions made preferred shares something of a trendy investment with interest rates so low following the financial crisis. But the Federal Reserve is restocking its toolkit and could soon ramp up its hiking pace; the solid August jobs report1 may help set the stage for two more rate increases before year-end. How might investors want to view preferreds and broad, market cap-weighted funds like the Global X U.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX NASH SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

4
MLP Monthly Report: September 2018

2018-10-15 seekingalpha
The September MLP Monthly Report can be found here offering insights on MLP industry news, the asset class’s performance, yields, valuations, and fundamental drivers.
KAAC APA SNSR AND LIT BFIT GXG SIL KRMA GXF CHII EV ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA BHI LNGR COPX QQQC GURU FANG

 
Income Monitor: Q2 2018

2018-10-15 seekingalpha
The Global X research team is excited to introduce the Income Monitor. This report seeks to provide broad, macro-level insights into the income characteristics of various asset classes and strategies. This quarter’s report can be accessed here.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

 
GURU August 2018 Rebalance Report

2018-10-15 seekingalpha
On August 23th, the Global X GURU Index ETF (NYSEARCA:GURU) underwent its quarterly rebalance. The August 2018 GURU Report can be found here.
SNSR AND LIT BFIT GXG SIL KRMA GXF CHII ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA LNGR COPX QQQC GURU

 
URA / Global X Funds 485BXT E-COMMERCE

2018-10-11 sec.gov
Document
URA

 
URA / Global X Funds 485BXT - GENOMICS

2018-10-11 sec.gov
Document
URA

 
URA / Global X Funds 40-17G

2018-10-10 sec.gov
Document <
URA

 
URA / Global X Funds 497

2018-10-05 sec.gov
Document <
URA

 
URA / Global X Funds 497

2018-10-05 sec.gov
Document <
URA

 
URA / Global X Funds 497

2018-10-05 sec.gov
Document <
URA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 37950E101